Latest Breaking News On - China national medical products administration - Page 4 : comparemela.com

Alphamab Oncology Announces the First Patient Dosed in a Phase I Clinical Study of HER3/TROP2 Bispecific ADC Drug JSKN016

SUZHOU, China, May 22, 2024 /PRNewswire/ — Alphamab Oncology (stock code: 9966.HK) announced that the first patient has been successfully dosed in the phase I…

Hong kongChina national medical products administrationAlphamab oncologyMain boardHong kong stock exchangeBreakthrough designationChina national medical products

Zai Lab and Innoviva Specialty Therapeutics Announce NMPA Approval for XACDURO® (Sulbactam-Durlobactam or SUL-DUR) for Hospital-Acquired and Ventilator-Associated Pneumonia Caused by Acinetobacter Baumannii-Calcoaceticus Complex in China

Drug-resistant Acinetobacter baumannii is a growing global health threat and high priority pathogen needing new antibiotics, according to World Health Organization China NMPA approval based on.

Hong kongNew zealandRepublic ofUnited statesHarald reinhartMatt ronsheimAcinetobacter baumanniiCenters for diseaseHead of global developmentZai lab limitedZai labSecurities exchangeInnoviva incDrug administrationZai lab forwardExchange commission

Zai Lab, Innoviva: China Oks XACDURO For Hospital-Acquired, Ventilator-Associated Pneumonia In 18+

Zai Lab Ltd. (ZLAB) and Innoviva Specialty Therapeutics announced Monday that China's National Medical Products Administration or NMPA has approved Zai Lab's New Drug Application for XACDURO (sulbactam-durlobactam) to treat hospital-acquired and ventilator-associated pneumonia caused by Acinetobacter baumannii-calcoaceticus complex in China.

Harald reinhartEntasis therapeutics incChina national medical products administrationHead of global developmentZai labZai lab new drug applicationDrug administrationZai lab ltdMore such health newsWorld health organizationInnoviva specialty therapeuticsNational medical products administrationNew drug applicationGreater chinaGlobal developmentInfectious diseases

China s NMPA approves Zai Lab s XACDURO NDA for pneumonia

The NMPA's decision was based on the positive outcomes of the Phase III ATTACK trial.

New zealandRepublic ofHarald reinhartDrug administrationZai labChina national medical products administrationInnoviva specialty therapeuticsNational medical products administrationEntasis therapeuticsGreater chinaPharmaceutical technology

Innoviva : Zai Lab and Innoviva Specialty Therapeutics Announce NMPA Approval for XACDURO® (Sulbactam Durlobactam or SUL DUR) for Hospital Acquired and Ventilator Associated Pneumonia Caused by Acinetobacter Baumannii Calcoaceticus Complex in China

Innoviva : Zai Lab and Innoviva Specialty Therapeutics Announce NMPA Approval for XACDURO® (Sulbactam Durlobactam or SUL DUR) for Hospital Acquired and Ventilator Associated Pneumonia Caused by Acinetobacter Baumannii Calcoaceticus Complex in China
marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.

Hong kongUnited statesNew zealandUnited kingdomRepublic ofAcinetobacter baumanniiHarald reinhartMatt ronsheimDrug administrationZai lab limitedHealth organizationCenters for diseaseZai lab new drug applicationEntasis therapeutics incZai labHead of global development